Reporting from ESMO Virtual Congress 2020, Paolo Ascierto gives an overview of important study results in Melanoma. He looks at interesting findings in patients with BRAF V600-mutant melanoma about treatment sequence for Immunotherapy and targeted therapy combinations, along with a triplet therapy study.
Regarding the use of pembrolizumab, he comments on confirmed results in terms of improving distant metastasis-free survival, and shows promising data about the combination with lenvatinib in patients who progressed to PD-1 or PL-L1 inhibitor.
Abstracts:
- LBA43 - Spartalizumab plus dabrafenib plus trametinib in patients with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: results from the randomized part 3 of the Phase III COMBI-i trial
- LBA45 - First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study)
- LBA44 - Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma that progressed on a PD-1 or PD-L1 inhibitor: initial results of LEAP-004
- LBA46 - Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase 3 trial
Produced by ESMO, [ Ссылка ]
This video was supported with a grant from Bayer Healthcare and Roche
